• Explore /
  • Poster
  • / Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).

Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).

Abstract Poster

Authors

null

Malcolm J. Moore

Princess Margaret Hospital, Toronto, ON, Canada

Malcolm J. Moore , Daniel D. Von Hoff , Thomas J. Ervin , Francis P. Arena , E. Gabriela Chiorean , Jeffrey R. Infante , Jeremy K. Hon , Mikhail Yu Biakhov , Sunil R. Hingorani , Vinod Ganju , Colin D. Weekes , Werner Scheithauer , Ramesh K. Ramanathan , Josep Tabernero , David Goldstein , Xinyu Wei , Alfredo Romano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT00844649

Citation

J Clin Oncol 31, 2013 (suppl; abstr 4059^)

DOI

10.1200/jco.2013.31.15_suppl.4059

Abstract #

4059^

Poster Bd #

18E

Abstract Disclosures

Similar Posters

First Author: E. Gabriela Chiorean

First Author: Akihiro Ohba

First Author: David Goldstein

First Author: David Goldstein